EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

Gilles Lemesle, Romain Didier, Philippe Gabriel Steg iD, Tabassome Simon, Gilles Montalescot, Nicolas Danchin, Christophe Bauters, Didier Blanchard, Claire Bouleti, Denis Angoulvant, Stéphane Andrieu, Gérald Vanzetto und 9 weitere

New England Journal of Medicine · 23.10.2025 · 393 (16) · 1578-1588

DOI: 10.1056/nejmoa2507532 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.10.2025. Verfasst von Gilles Lemesle und 20 weiteren Autor:innen. Beteiligte Einrichtung: Heart and Lung Institute, University Hospital of Lille, Centre Hospitalier Universitaire (CHU) Lille, Lille, France. Hauptthemen laut MEDLINE: Anticoagulants, Aspirin, Platelet Aggregation Inhibitors, Coronary Disease. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Ministère des Affaires Sociales et de la Santé, Bayer HealthCare, French Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAspirinPlatelet Aggregation InhibitorsCoronary DiseaseThrombosisAgedFemaleHumansMaleMiddle AgedAdministration, OralChronic DiseaseDouble-Blind MethodHemorrhageKaplan-Meier EstimateMyocardial InfarctionStrokePeripheral Arterial DiseaseFollow-Up StudiesPercutaneous Coronary InterventionFranceAged, 80 and overDrug Therapy, Combination

Substanzen

AnticoagulantsAspirinPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Heart and Lung Institute, University Hospital of Lille, Centre Hospitalier Universitaire (CHU) Lille, Lille, France.
  • Institut Pasteur de Lille, INSERM Unité 1011, Lille, France.
  • Université de Lille, Lille, France.
  • French Alliance for Cardiovascular Trials, Paris.
  • Cardiology Department, CHU Brest, Brest, France.
  • INSERM Unité Mixte de Recherche (UMR) 1304-Groupe d'Études Tumeurs et Biothérapies Oncologiques (GETBO) Brest, France.

ORCID-Profile: Philippe Gabriel Steg

Förderung

  • Ministère des Affaires Sociales et de la Santé
  • Bayer HealthCare
  • French Ministry of Health

Zitieren

APA

Lemesle, G., Didier, R., Steg, P. G., Simon, T., Montalescot, G., Danchin, N., Bauters, C., Blanchard, D., Bouleti, C., Angoulvant, D., Andrieu, S., Vanzetto, G., Kerneis, M., Decalf, V., Puymirat, E., Mottier, D., Diallo, A., Vicaut, E., Gilard, M., …, & AQUATIC Trial Investigators (2025). Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. New England Journal of Medicine, 393(16), 1578-1588. https://doi.org/10.1056/nejmoa2507532

Vancouver

Lemesle G, Didier R, Steg PG, Simon T, Montalescot G, Danchin N, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. New England Journal of Medicine. 2025;393(16):1578-1588. doi:10.1056/nejmoa2507532

BibTeX
@article{Lemesle2025,
  author = {Lemesle, Gilles and Didier, Romain and Steg, Philippe Gabriel and Simon, Tabassome and Montalescot, Gilles and Danchin, Nicolas and Bauters, Christophe and Blanchard, Didier and Bouleti, Claire and Angoulvant, Denis and Andrieu, Stéphane and Vanzetto, Gérald and Kerneis, Mathieu and Decalf, Véronique and Puymirat, Etienne and Mottier, Dominique and Diallo, Abdourahmane and Vicaut, Eric and Gilard, Martine and Cayla, Guillaume and AQUATIC Trial Investigators, AQUATIC Trial Investigators},
  title = {Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {16},
  pages = {1578--1588},
  doi = {10.1056/nejmoa2507532}
}
Kostenlos starten →